Floatz logo

Irinotecan

Liver Neoplasms

Tehran University of Medical SciencesSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Liver Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Shanghai Zhongshan Hospital
Phase 4BB
ALBUMIN AGGREGATED
Sirtex Medical
Phase 4BB
CHLORHEXIDINE
Changhua Christian Hospital
Phase 4BB
Talaporfin
Light Sciences Oncology
Phase 3BB
FLUOROURACILUM
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →